Key clinical point: Highly elevated antidrug antibody (ADA) levels (≥1,000 ng/mL) at 3 weeks (cycle 2 day 1 [C2D1]) may be associated with poor clinical outcomes after atezolizumab/bevacizumab (Atezo/Bev) treatment in patients with advanced hepatocellular carcinoma (HCC).
Major finding: In both discovery cohort (DC) and validation cohort (VC), patients with high vs low ADA levels at C2D1 had worse progression-free survival (DC: hazard ratio [HR] 2.84; P = .005; VC: HR 2.52; P = .006) and overall survival (DC: HR 3.30; P = .003; VC: HR 5.81; P = .001).
Study details: This prospective cohort study included 132 patients with advanced HCC treated with first-line Atezo/Bev (DC n = 50; VC n = 82).
Disclosures: This study was sponsored by a National Research Foundation of Korea grant funded by the Korean government and others. Some authors reported serving as advisors for or receiving personal fees or grants from various sources. Two authors declared having a pending method patent for predicting therapeutic response to biologic drugs by quantifying blood ADA.
Source: Kim C et al. Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol . 2022 (Oct 20). Doi: 10.1001/jamaoncol.2022.4733
